{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:56:43Z","timestamp":1774558603818,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,12,16]],"date-time":"2002-12-16T00:00:00Z","timestamp":1039996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1038\/nm811","type":"journal-article","created":{"date-parts":[[2003,1,3]],"date-time":"2003-01-03T19:13:06Z","timestamp":1041621186000},"page":"47-52","source":"Crossref","is-referenced-by-count":304,"title":["Cytokine traps: multi-component, high-affinity blockers of cytokine action"],"prefix":"10.1038","volume":"9","author":[{"given":"Aris N.","family":"Economides","sequence":"first","affiliation":[]},{"given":"Laura Rocco","family":"Carpenter","sequence":"additional","affiliation":[]},{"given":"John S.","family":"Rudge","sequence":"additional","affiliation":[]},{"given":"Vivien","family":"Wong","sequence":"additional","affiliation":[]},{"given":"Ellen M.","family":"Koehler-Stec","sequence":"additional","affiliation":[]},{"given":"Christopher","family":"Hartnett","sequence":"additional","affiliation":[]},{"given":"Erica A.","family":"Pyles","sequence":"additional","affiliation":[]},{"given":"Xiaobing","family":"Xu","sequence":"additional","affiliation":[]},{"given":"Thomas J.","family":"Daly","sequence":"additional","affiliation":[]},{"given":"Michael R.","family":"Young","sequence":"additional","affiliation":[]},{"given":"James P.","family":"Fandl","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Scott","family":"Carver","sequence":"additional","affiliation":[]},{"given":"Jennifer","family":"McNay","sequence":"additional","affiliation":[]},{"given":"Kevin","family":"Bailey","sequence":"additional","affiliation":[]},{"given":"Swayampakula","family":"Ramakanth","sequence":"additional","affiliation":[]},{"given":"Renta","family":"Hutabarat","sequence":"additional","affiliation":[]},{"given":"Tammy T.","family":"Huang","sequence":"additional","affiliation":[]},{"given":"Czeslaw","family":"Radziejewski","sequence":"additional","affiliation":[]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[]},{"given":"Neil","family":"Stahl","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2002,12,16]]},"reference":[{"issue":"Suppl. 1","key":"BFnm811_CR1","doi-asserted-by":"publisher","first-page":"I114","DOI":"10.1136\/ard.58.2008.i114","volume":"58","author":"SJ van Deventer","year":"1999","unstructured":"van Deventer, S.J. Anti-TNF antibody treatment of Crohn's disease. Ann. Rheum. Dis. 58 (Suppl. 1), I114\u20131120 (1999).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnm811_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00063030-200115040-00005","volume":"15","author":"C Richard-Miceli","year":"2001","unstructured":"Richard-Miceli, C. & Dougados, M. Tumour necrosis factor-\u03b1 blockers in rheumatoid arthritis: Review of the clinical experience. Biodrugs 15, 251\u2013259 (2001).","journal-title":"Biodrugs"},{"key":"BFnm811_CR3","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor \u03b1. Arthritis Rheum. 36, 1681\u20131690 (1993).","journal-title":"Arthritis Rheum."},{"key":"BFnm811_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0149-2918(00)88269-7","volume":"21","author":"MM Goldenberg","year":"1999","unstructured":"Goldenberg, M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther. 21, 75\u201387 (1999).","journal-title":"Clin. Ther."},{"key":"BFnm811_CR5","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","volume":"151","author":"KM Mohler","year":"1993","unstructured":"Mohler, K.M. et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151, 1548\u20131561 (1993).","journal-title":"J. Immunol."},{"key":"BFnm811_CR6","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","volume":"41","author":"B Bresnihan","year":"1998","unstructured":"Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196\u20132204 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnm811_CR7","doi-asserted-by":"publisher","first-page":"S273","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"S Cohen","year":"1999","unstructured":"Cohen, S., Hurd, E. & Cush, J. Treatment of interleukin-1 receptor antagonist in combination with methotrexate in rheumatoid arthritis patients. Arthritis Rheum. 42, S273 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnm811_CR8","first-page":"S224","volume":"40","author":"G Nuki","year":"1997","unstructured":"Nuki, G., Rozman, B. & Pavelka, K. Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis. Arthritis Rheum. 40, S224 (1997).","journal-title":"Arthritis Rheum."},{"key":"BFnm811_CR9","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/art.1780390704","volume":"39","author":"GV Campion","year":"1996","unstructured":"Campion, G.V., Lebsack, M.E., Lookabaugh, J., Gordon, G. & Catalano, M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. 39, 1092\u20131101 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnm811_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2165\/00063030-200115020-00003","volume":"15","author":"B Bresnihan","year":"2001","unstructured":"Bresnihan, B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Biodrugs 15, 87\u201397 (2001).","journal-title":"Biodrugs"},{"key":"BFnm811_CR11","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1164\/ajrccm.160.6.9808146","volume":"160","author":"LC Borish","year":"1999","unstructured":"Borish, L.C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I\/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816\u20131823 (1999).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnm811_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1067\/mai.2001.115624","volume":"107","author":"LC Borish","year":"2001","unstructured":"Borish, L.C. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963\u2013970 (2001).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnm811_CR13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V86.2.685.bloodjournal862685","volume":"86","author":"R Bataille","year":"1995","unstructured":"Bataille, R. et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86, 685\u2013691 (1995).","journal-title":"Blood"},{"key":"BFnm811_CR14","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1182\/blood.V97.6.1590","volume":"97","author":"E Haddad","year":"2001","unstructured":"Haddad, E. et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 97, 1590\u20131597 (2001).","journal-title":"Blood"},{"key":"BFnm811_CR15","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1056\/NEJM199403033300904","volume":"330","author":"JT Beck","year":"1994","unstructured":"Beck, J.T. et al. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Engl. J. Med. 330, 602\u2013605 (1994).","journal-title":"N. Engl. J. Med."},{"key":"BFnm811_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2249.1994.tb06145.x","volume":"98","author":"E Legouffe","year":"1994","unstructured":"Legouffe, E. et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin. Exp. Immunol. 98, 323\u2013329 (1994).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnm811_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0065-3233(08)60434-9","volume":"52","author":"LR Carpenter","year":"1999","unstructured":"Carpenter, L.R., Yancopoulos, G.D. & Stahl, N. General mechanisms of cytokine receptor signaling. Adv. Protein Chem. 52, 109\u2013140 (1999).","journal-title":"Adv. Protein Chem."},{"key":"BFnm811_CR18","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1126\/science.8390097","volume":"260","author":"S Davis","year":"1993","unstructured":"Davis, S. et al. LIFR \u03b2 and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science 260, 1805\u20131808 (1993).","journal-title":"Science"},{"key":"BFnm811_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/0092-8674(93)90506-L","volume":"74","author":"N Stahl","year":"1993","unstructured":"Stahl, N. & Yancopoulos, G.D. The alphas, betas, and kinases of cytokine receptor complexes. Cell 74, 587\u2013590 (1993).","journal-title":"Cell"},{"key":"BFnm811_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0092-8674(89)90438-8","volume":"58","author":"T Taga","year":"1989","unstructured":"Taga, T. et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58, 573\u2013581 (1989).","journal-title":"Cell"},{"key":"BFnm811_CR21","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","volume":"87","author":"CA Dinarello","year":"1996","unstructured":"Dinarello, C.A. Biologic basis for interleukin-1 in disease. Blood 87, 2095\u20132147 (1996).","journal-title":"Blood"},{"key":"BFnm811_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2249.1994.tb06517.x","volume":"95","author":"WB van den Berg","year":"1994","unstructured":"van den Berg, W.B., Joosten, L.A., Helsen, M. & van de Loo, F.A. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95, 237\u2013243 (1994).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnm811_CR23","first-page":"157","volume":"45","author":"J Reimers","year":"1998","unstructured":"Reimers, J. Interleukin-1b induced transient diabetes mellitus in rats. Danish Med. Bull. 45, 157\u2013180 (1998).","journal-title":"Danish Med. Bull."},{"key":"BFnm811_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/BF00832004","volume":"20","author":"WB van den Berg","year":"1998","unstructured":"van den Berg, W.B. Joint inflammation and cartilage destruction may occur uncoupled. Springer Semin. Immunopathol. 20, 149\u2013164 (1998).","journal-title":"Springer Semin. Immunopathol."},{"key":"BFnm811_CR25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/art.1780390513","volume":"39","author":"LA Joosten","year":"1996","unstructured":"Joosten, L.A., Helsen, M.M., van de Loo, F.A. & van den Berg, W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice. A comparative study using anti-TNF \u03b1, anti- IL-1 \u03b1\/\u03b2, and IL-1Ra. Arthritis Rheum. 39, 797\u2013809 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnm811_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1172\/JCI7010","volume":"104","author":"G Cieslewicz","year":"1999","unstructured":"Cieslewicz, G. et al. The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. J. Clin. Invest. 104, 301\u2013308 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnm811_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev.immunol.17.1.255","volume":"17","author":"M Wills-Karp","year":"1999","unstructured":"Wills-Karp, M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17, 255\u2013281 (1999).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnm811_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1365-2222.1996.tb00599.x","volume":"26","author":"R Gundel","year":"1996","unstructured":"Gundel, R. et al. IL-4 induced leucocyte trafficking in cynomolgus monkeys: correlation with expression of adhesion molecules and chemokine generation. Clin. Exp. Allergy 26, 719\u2013729 (1996).","journal-title":"Clin. Exp. Allergy"},{"key":"BFnm811_CR29","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1073\/pnas.92.5.1254","volume":"92","author":"J Foote","year":"1995","unstructured":"Foote, J. & Eisen, H.N. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 92, 1254\u20131256 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm811_CR30","unstructured":"Guler, H.-P. et al. A phase 1, single dose escalation study of IL-1 trap in patients with rheumatoid arthritis. Arthritis Rheum. 44, S370 (2001)."},{"key":"BFnm811_CR31","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1126\/science.282.5397.2258","volume":"282","author":"M Wills-Karp","year":"1998","unstructured":"Wills-Karp, M. et al. Interleukin-13: central mediator of allergic asthma. Science 282, 2258\u20132261 (1998).","journal-title":"Science"},{"key":"BFnm811_CR32","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1126\/science.282.5397.2261","volume":"282","author":"G Grunig","year":"1998","unstructured":"Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261\u20132263 (1998).","journal-title":"Science"},{"key":"BFnm811_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1165\/ajrcmb.13.1.7598937","volume":"13","author":"AJ Coyle","year":"1995","unstructured":"Coyle, A.J. et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am. J. Respir. Cell Mol. Biol. 13, 54\u201359 (1995).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"BFnm811_CR34","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash, J. et al. VEGF-trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99, 11393\u201311398 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm811_CR35","doi-asserted-by":"publisher","first-page":"11399","DOI":"10.1073\/pnas.172398399","volume":"99","author":"ES Kim","year":"2002","unstructured":"Kim, E.S. et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA 99, 11399\u201311404 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm811_CR36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1365-2249.1994.tb06069.x","volume":"97","author":"LA Joosten","year":"1994","unstructured":"Joosten, L.A., Helsen, M.M. & van den Berg, W.B. Accelerated onset of collagen-induced arthritis by remote inflammation. Clin. Exp. Immunol. 97, 204\u2013211 (1994).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnm811_CR37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/art.1780360915","volume":"36","author":"PH Wooley","year":"1993","unstructured":"Wooley, P.H. et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum. 36, 1305\u20131314 (1993).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm811.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm811","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm811.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:33:16Z","timestamp":1684449196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,16]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["BFnm811"],"URL":"https:\/\/doi.org\/10.1038\/nm811","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12,16]]}}}